Praluent for people with prior history of heart attack or stroke who’ve already tried a statin
FRIDAY, July 24, 2015 (HealthDay News) — The U.S. Food and Drug Administration on Friday approved Praluent, the first of a powerful new class of injected, cholesterol-lowering drugs that experts believe could change cardiovascular care.
Praluent (alirocumab) sharply cuts levels of LDL (“bad”) cholesterol, and is one of a group of newly developed drugs called PCSK9 inhibitors, the FDA explained in a news release.
The drug is only approved for patients with heart disease and a history of heart attack or stroke “who require additional lowering of LDL cholesterol” in addition to taking a statin drug and adopting a healthy diet, the agency said.
For more information please visit FDA website.
Disclaimer: The EDC Developer blog is “one man’s opinion”. Anything that is said on the report is either opinion, criticism, information or commentary, If making any type of investment or legal decision it would be wise to contact or consult a professional before making that decision.